SCHEMBL3547095

SCHEMBL3547095

COc1ccc(C2CNC(=O)C2)cc1OCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 20/20 1.00
PDE4B Q07343 14/20 1.00
PDE4C Q08493 14/20 1.00
PDE4D Q08499 14/20 1.00
CYP3A4 P08684 2/20 0.60
VEGFA P15692 1/20 0.60
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
CYP1A2 P05177 1/20 0.60
MAPT P10636 1/20 0.60
CYP2C9 P11712 1/20 0.60
ALOX15 P16050 1/20 0.60
CREBBP Q92793 1/20 0.60
KDM4E B2RXH2 1/20 0.60
PDE5A O76074 1/20 0.60
TNF P01375 1/20 0.60
MAPK1 P28482 1/20 0.60
BLM P54132 1/20 0.60
PDE1A P54750 1/20 0.60
PDE1B Q01064 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9341618 1.00 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL13439292 1.00 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL3551708 0.89 PDE4A (0.80) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL3542652 0.88 PDE4A (0.78) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL3549567 0.87 PDE4A (0.77) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL4458628 0.85 PDE4A (0.74) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL4466602 0.85 PDE4A (0.74) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL3539960 0.85 PDE4A (0.74) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL4197597 0.85 PDE4A (0.73) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL4199760 0.85 PDE4A (0.73) PDE4APDE4BPDE4CPDE4DCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0437555-A1 PROCESS FOR THE RACEMIC SEPARATION OF 4-ARYL-2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID ESTERS. SCHERING AG (DE) 1991-07-24 EP claimed
WO-1991000362-A1 PROCESS FOR THE RACEMIC SEPARATION OF 4-ARYL-2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID ESTERS SCHERING AKTIENGESELLSCHAFT (DE) 1991-01-10 WO claimed
US-4193926-A 4-(Polyalkoxy phenyl)-2-pyrrolidones SCHERING AKTIENGESELLSCHAFT (DE) 1980-03-18 US claimed
US-4012495-A USED IN TREATING NEUROLOGICAL AND PSYCHIC DISORDERS SCHERING AKTIENGESELLSCHAFT (DT) 1977-03-15 US claimed
US-7696198-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2010-04-13 US disclosed
US-20090306156-A1 PHOSPHODIESTERASE 4 INHIBITORS HOPPER ALLEN 2009-12-10 US disclosed
US-7601742-B2 4-(3-Hydroxy-4-methoxyphenyl)-pyrrolidin-2-one and derivatives; reverse transcriptase inhibitors; AIDS IRM LLC (BM) 2009-10-13 US disclosed
US-7601742-B2 4-(3-Hydroxy-4-methoxyphenyl)-pyrrolidin-2-one and derivatives; reverse transcriptase inhibitors; AIDS IRM LLC (BM) 2009-10-13 US disclosed
US-7601742-B2 4-(3-Hydroxy-4-methoxyphenyl)-pyrrolidin-2-one and derivatives; reverse transcriptase inhibitors; AIDS IRM LLC (BM) 2009-10-13 US disclosed
EP-1435944-B1 4(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES MEMORY PHARM CORP (US) 2009-09-30 EP disclosed
US-7585882-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2009-09-08 US disclosed
US-20090176799-A1 PHOSPHODIESTERASE 4 INHIBITORS RUIPING LIU 2009-07-09 US disclosed
US-20030139406-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-07-24 US disclosed
WO-2003032981-A1 4-(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES MEMORY PHARMACEUTICALS CORPORATION (US) 2003-04-24 WO disclosed
US-5539111-A Process for resolution of racemates of 4-aryl-2-oxo-pyrrolidine-3-carboxylic acid esters SCHERING AKTIENGESELLSCHAFT (DE) 1996-07-23 US disclosed
EP-0437555-B1 PROCESS FOR THE RACEMIC SEPARATION OF 4-ARYL-2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID ESTERS SCHERING AG (DE) 1995-08-30 EP disclosed
EP-0437555-A1 PROCESS FOR THE RACEMIC SEPARATION OF 4-ARYL-2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID ESTERS. SCHERING AG (DE) 1991-07-24 EP disclosed
WO-1991000362-A1 PROCESS FOR THE RACEMIC SEPARATION OF 4-ARYL-2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID ESTERS SCHERING AKTIENGESELLSCHAFT (DE) 1991-01-10 WO disclosed
US-4193926-A 4-(Polyalkoxy phenyl)-2-pyrrolidones SCHERING AKTIENGESELLSCHAFT (DE) 1980-03-18 US disclosed
US-4012495-A USED IN TREATING NEUROLOGICAL AND PSYCHIC DISORDERS SCHERING AKTIENGESELLSCHAFT (DT) 1977-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139406-A1 Phosphodiesterase 4 inhibitors PDE12, PDE4A, PDE5A PDE4A 2/4885PDE4B 7/4885PDE4C 8/4885
US-20090176799-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE12, PDE3B PDE4A 1/4885PDE4B 5/4885PDE4C 8/4885
US-20090306156-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE5A PDE4A 1/4885PDE4B 5/4885PDE4C 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.